Dr Rachel Abbott | Group Leader, Preclinical Research
Adaptimmune Ltd

Dr Rachel Abbott, Group Leader, Preclinical Research, Adaptimmune Ltd

Rachel Abbott, M.Biochem, D.Phil,
Group Leader, Preclinical Research, Adaptimmune Ltd.
Rachel Abbott was awarded her D.Phil from the University of Oxford in 2007, where she carried out structural studies of the complement system regulator CD55 under Prof Susan Lea. This was followed by seven years working as post-doctoral research fellow in Prof Alan Rickinson’s lab at the University of Birmingham, studying CD8+ T cell responses to Epstein Barr virus. Rachel joined Adaptimmune as a Senior Scientist in 2014 and is now a Group Leader within the Preclinical Research department. She manages a team responsible for evaluating new and affinity-enhanced TCRs for potency and specificity and has recently led a number of preclinical programs, in which novel SPEARTM T cell products have been assessed for specificity and safety using Adaptimmune’s current extensive in vitro preclinical safety screening process.


Day 3 Oct 12th Immune Profiling @ 13:20

Engineering 2nd Generation SPEAR™-T cells to Overcome TGF-β-Mediated Immunosuppression

  • NY-ESO SPEAR-T cells show promise in clinical trials for solid and liquid tumours
  • Depth and durability of responses may be affected by inhibitory cytokines such as Transforming Growth Factor-β (TGF-β) in the tumour microenvironment
  • Preclinical assessment of a dominant negative TGF-β receptor (dnTGFβRII) to make T cells resistant to the inhibitory effects of TGF-β

back to speakers